Tag: ACS

1. A prospective observational study demonstrated moderate agreement between clinicians and researchers in assigning patients a HEART score. Evidence Rating Level: 2 (Good) The HEART score is a risk stratification aid used frequently in emergency departments (ED) to estimate the probability of major adverse cardiac events within 30 days for...
1. The PRAISE score showed accurate discriminative capabilities for the prediction of all-cause death, acute myocardial infarction, and major bleeding after an acute coronary syndrome. 2. Compared with low risk stratification, a high-risk PRAISE score was associated with a 58.8-times increase in death, 27.7-times increase in myocardial infarction, and a...
1. Low BMI, Killip class 3/4, history of previous MI, use of mechanical support, and flow worsening were shown to be significantly associated with major adverse cardiac events (MACE) in patients with an ST-elevation myocardial infarction (STEMI) who have achieved a door-to-balloon time (DTBT) under 90 minutes. 2. Radial access...
1. There does not appear to be any difference in outcome between pre- and post-treatment administration of P2Y12 inhibitors among patients experiencing a non-ST elevation acute coronary syndrome with planned invasive intervention. 2. Prasugrel and ticagrelor showed similar outcomes when administered post-treatment. Evidence Rating Level: 1 (Excellent) Though it is well established...
Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome 1. There does not appear to be any difference in outcome between pre- and post-treatment administration of P2Y12 inhibitors among patients experiencing a non-ST elevation acute coronary syndrome with planned invasive intervention. 2. Prasugrel and ticagrelor showed similar outcomes...
1. Among patients that suffered a recent acute coronary syndrome (ACS) and had elevated levels of atherogenic lipoproteins despite intensive or maximum-intensive statin therapy, alirocumab reduced the number of recurrent cardiovascular ischemic events. This response was more robust with higher levels of low-density lipoprotein (LDL) cholesterol. 2. The safety profile...
1. In this prespecified secondary analysis of a randomized controlled trial, patients with acute coronary syndrome (ACS) who received a loading dose of atorvastatin prior to percutaneous coronary intervention (PCI) and again 24 hours post-PCI had lower rates of major adverse cardiovascular events at 30 days compared with patients...
1. From a cohort study of Danish patients presenting with acute coronary syndrome, early invasive revascularization interventions were associated with reduced cardiac mortality when compared to conservative invasive strategies. 2. Early intervention was also associated with decreased all-cause mortality and re-hospitalization within 60 days compared to conservative intervention. Evidence Rating Level:...
1. This meta-analysis of outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI) showed that women fared similarly to men in terms of hospital mortality and 1-year mortality, after adjusting for major confounding variables. 2. There were major differences in the baseline characteristics between women and men,...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure The PARADIGM-HF trial Inhibition of neprilysin, an endopeptidase that degrades endogenous vasoactive peptides, has been shown to counteract the maladaptive vasoconstriction, sodium retention, and remodelling processes...